Latest News

Combining multiple PDFs into a single file is one of the simplest ways to cut down on digital clutter and make sharing documents easier. Managing separate files for reports, invoices, or receipts adds up quickly, and merging them into one solves that directly. Depending on your device and how much control you want over the [...]

Forget the quantum computing pure plays -- Microsoft is in a unique position in this space.

Executives from Healios and SAB Biotherapeutics (NASDAQ:SABS) outlined their approaches to developing scalable biologic therapies during a Chardan discussion focused on complex treatments designed for commercial manufacturing. Healios Chief Financial Officer Rich Kincaid discussed the company’s mul

Architectural specifications and the adoption of electronic locks create multiyear revenue visibility that pricing discipline alone cannot explain.

Both companies are experiencing sales growth but also substantial losses.

Cancellations now stem from clinical failures rather than funding shortages, signaling a healthier market for contract research.

Margin gains from internal brewing are offsetting volume declines, but new high-margin brands will determine if that cushion holds.

The EV maker's operating profit recovered last quarter. But was a one-off bump behind it?

Sun Cruiser surges 60% as gross margins hit highest level since 2017.

Record adjusted net income and improved cost guidance signal production growth ahead.

Management's refusal to chase loan volume with looser terms is the real test of whether cost discipline can sustain earnings growth.

Operational efficiency gains are offsetting cost inflation, underpinning the company's ability to sustain margin expansion.

The beverage and snacks titan has been the fast-food purveyor's exclusive beverage partner for decades.

Production ramps create near-term cost pressure, but management sees a clear path to 18% operating margins by decade's end.

Media revenue jumped over 10% as synergy gains drive margin expansion.

HOKA and UGG drive record revenue despite promotional headwinds and logistics disruptions.

Revenue surged 55% as cloud storage demand and AI infrastructure investments accelerated.

The company is converting capital markets infrastructure into high-margin recurring revenue, a structural shift that insulates profitability from trading volatility.

Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer and a mutant calreticulin, or mCALR, program for myeloproliferative neoplasms.

Cost discipline and moderating capital spending are freeing up cash flow for shareholder returns.

Pricing power and operational discipline held margins steady even as sales flatlined, signaling resilience beyond the current channel turbulence.

Higher charge-offs and lower earnings guidance offset the strategic wins from new funding partnerships and loan retention.

Wood's Ark Invest is building back its exposure to Netflix.

Management closed nine branches to boost annual pre-tax income by $2.3M–$2.7M.

A $1.4 billion cost headwind this year tests whether innovation-backed pricing can sustain margin protection without sacrificing volume.